Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11159-11170

  Li, Xiaoying ^a   Shao, Minhua ^b   Wang, Shiming ^a   Zhao, Xueying ^a   Chen, Hongyan ^a   Qian, Ji ^a   Song, Xiao ^a   Wang, Jiucun ^a   Jin, Li ^a   Wu, Junjie ^a   Li, Qiang ^c   Bai, Chunxue ^d   Han, Baohui ^b   Gao, Zhiqiang ^b   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Clinical outcomes; Methylenetetrahydrofolate reductase; Non small cell lung cancer; Platinum based chemotherapy; Polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; GEMCITABINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; NAVELBINE; PACLITAXEL; TAXOID; VINBLASTINE;

ADENOCARCINOMA; ADULT; AGED; ANALOGS AND DERIVATIVES; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PACLITAXEL; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; VINBLASTINE;

EID: 84927799672     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2427-6     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
2. Zhao X, Wang X, Wu W, Gao Z, Wu J, Garfield DH, et al. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy. Cancer. 2012;118(14):3587–98. doi:10.1002/cncr.26669.
3. Wang L, Liao ML, Li LY, Wan HY, Xu N, Liu JW, et al. Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study. Chin Med J (Engl). 2004;117(11):1607–10.
4. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer. 2011;72(2):238–43. doi:10.1016/j.lungcan.2010.09.001.
5. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4945–52. doi:10.1200/JCO.2010.30.5334.
6. Kim YI. Role of folate in colon cancer development and progression. J Nutr. 2003;133(11 Suppl 1):3731S–9.
7. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–3. doi:10.1038/ng0595-111.
8. Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei. China Lung Cancer. 2005;49(3):299–309. doi:10.1016/j.lungcan.2005.04.002.
9. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A. 1997;94(7):3290–5.
10. Crott JW, Mashiyama ST, Ames BN, Fenech M. The effect of folic acid deficiency and MTHFR C677T polymorphism on chromosome damage in human lymphocytes in vitro. Cancer Epidemiol Biomarkers Prev. 2001;10(10):1089–96.
11. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475(1–2):7–20.
12. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg. 2001;234(1):10–20.
13. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2013. doi:10.1136/gutjnl-2012-304219.
14. Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011;17(11):3822–9. doi:10.1158/1078-0432.CCR-11-0304.
15. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, et al. The 1298A– > C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156(2):409–15.
16. Hong W, Wang K, Zhang YP, Kou JY, Hong D, Su D, et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J Zhejiang Univ Sci B. 2013;14(3):207–15. doi:10.1631/jzus.B1200101.
17. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS. Influence of polymorphisms in MTHFR 677 C– > T, TYMS 3R– > 2R and MTR 2756 A– > G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics. 2011;12(6):797–808. doi:10.2217/pgs.11.27.
18. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(12):2038–45. doi:10.1200/JCO.2008.19.1650.
19. Shi M, Gao C, Wu J, Feng J, Cao H, Lu J, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2006;9(6):519–24. doi:10.3779/j.issn.1009-3419.2006.06.09.
20. Alberola V, Sarries C, Rosell R, Taron M, de las Penas R, Camps C, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer. 2004;5(6):360–5.
21. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012;78(1):92–9. doi:10.1016/j.lungcan.2012.07.009.
22. Li WJ, Jiang H, Fang XJ, Ye HL, Liu MH, Liu YW, et al. Polymorphisms in thymidylate synthase and reduced folate carrier () genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett. 2013;5(4):1165–70. doi:10.3892/ol.2013.1175.
23. Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, et al. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 2011;32(12):1867–71. doi:10.1093/carcin/bgr217.
24. Yan Y, Gong Z, Zhang L, Li Y, Li X, Zhu L, et al. Association of follicle-stimulating hormone receptor polymorphisms with ovarian response in Chinese women: a prospective clinical study. PLoS One. 2013;8(10):e78138. doi:10.1371/journal.pone.0078138.
25. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2383–90. doi:10.1158/1078-0432.CCR-09-2793.
26. Stone N, Pangilinan F, Molloy AM, Shane B, Scott JM, Ueland PM, et al. Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genes. Plos One. 2011;6(7):e21851. doi:10.1371/journal.pone.0021851.
27. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. doi:10.1016/s0092-8674(04)00045-5.
28. Grubb BR, Gabriel SE. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis. Am J Physiol. 1997;273(2 Pt 1):G258–66.
29. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood. 2010;115(23):4820–3. doi:10.1182/blood-2010-01-266775.
30. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, et al. Implication of BRCA2–26G > A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res BCR. 2007;9(5):R71. doi:10.1186/bcr1780.
31. Cagliani R, Riva S, Marino C, Fumagalli M, D’Angelo MG, Riva V, et al. Variants in SNAP25 are targets of natural selection and influence verbal performances in women. Cell Mol Life Sci CMLS. 2012;69(10):1705–15. doi:10.1007/s00018-011-0896-y.
32. Huebner C, Browning BL, Petermann I, Han DY, Philpott M, Barclay M, et al. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009;15(12):1784–93. doi:10.1002/ibd.21019.
33. Kim YI. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol. 2009;5(4):523–42. doi:10.2217/fon.09.26.
34. Igari S, Ohtaki A, Yamanaka Y, Sato Y, Yohda M, Odaka M, et al. Properties and crystal structure of methylenetetrahydrofolate reductase from Thermus thermophilus HB8. PLoS One. 2011;6(8):e23716. doi:10.1371/journal.pone.0023716.
35. Pejchal R, Campbell E, Guenther BD, Lennon BW, Matthews RG, Ludwig ML. Structural perturbations in the Ala – > Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry. 2006;45(15):4808–18. doi:10.1021/bi052294c.
36. DeVos L, Chanson A, Liu Z, Ciappio ED, Parnell LD, Mason JB, et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr. 2008;88(4):1149–58.
37. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol / ESMO. 2009;20(10):1660–6. doi:10.1093/annonc/mdp046.
38. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62(5):1044–51. doi:10.1086/301825.
39. Tsai SJ, Hong CJ, Yeh HL, Liou YJ, Yang AC, Liu ME, et al. Heterozygote advantage of the MTHFR C677T polymorphism on specific cognitive performance in elderly Chinese males without dementia. Dement Geriatr Cogn Disord. 2011;32(3):159–63. doi:10.1159/000333074.
40. Weitkamp LR, Tackels DC, Hunter AG, Holmes LB, Schwartz CE. Heterozygote advantage of the MTHFR gene in patients with neural-tube defect and their relatives. Lancet. 1998;351(9115):1554–5.
41. Spellicy CJ, Northrup H, Fletcher JM, Cirino PT, Dennis M, Morrison AC, et al. Folate metabolism gene 5,10-methylenetetrahydrofolate reductase (MTHFR) is associated with ADHD in myelomeningocele patients. PLoS One. 2012;7(12):e51330. doi:10.1371/journal.pone.0051330.
42. Cheng X, Li T, Wang H, Zhu D, Ma C, Ma B, et al. Methylenetetrahydrofolate reductase gene polymorphisms and cerebral palsy in Chinese infants. J Hum Genet. 2011;56(1):17–21. doi:10.1038/jhg.2010.127.
43. Wu C, Gong Y, Sun A, Zhang Y, Zhang C, Zhang W, et al. The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding. Nutr Metab Cardiovasc Dis NMCD. 2013;23(7):693–8. doi:10.1016/j.numecd.2012.02.009.
44. Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006;81(3):1021–7. doi:10.1016/j.athoracsur.2005.09.020.
45. Park SY, Lee JG, Kim J, Bae MK, Lee CY, Kim DJ, et al. The influence of smoking intensity on the clinicopathologic features and survival of patients with surgically treated non-small cell lung cancer. Lung Cancer. 2013;81(3):480–6. doi:10.1016/j.lungcan.2013.07.002.